Estrogen Receptor Signaling in the Endometrium: pathway analysis of agonists and antagonists
Year: 2005
Type: dissertation
Abstract: Endometrial cancer is the most common gynecological malignancy in Europe and the USA. In the \nnormal endometrium, growth and differentiation is controlled by the ovarian hormones estrogen \nand progesterone. After menopause, the absence of follicle recruitment in the ovary results in a \ndecline in serum levels of estrogen and progesterone, and consequently results in an \natrophic/inactive state of the endometrium. However, in some women increased levels of \nestrogen (either endogenous or exogenous) are present, which will stimulate the endometrium. \nThis estrogen-induced growth of the endometrium may result in uncontrolled growth, which can \neventually develop into cancer. As in the normal endometrium, progesterone inhibits growth of \nendometrial cancer cells and is therefore used in the clinic as adjuvant therapy. \n\nTamoxifen, a selective estrogen receptor modulator (SERM), is standard adjuvant \ntherapy for patients with estrogen receptor positive (ER+) breast cancer (estrogen-antagonistic \neffect). In the endometrium, however, tamoxifen displays an estrogen-agonistic effect, and use \nof tamoxifen is therefore associated with an increased risk for development of endometrial \npathologies, including endometrial cancer. \n\nFor the endometrium, but also for many other organs, growth factors and growth factor \nreceptors play a central role in mediating the effects of steroid hormones. Growth factors like \nIGF-1 and EGF mediate estrogen receptor signaling and are therefore also involved in the \nregulation of proliferation of the endometrium and endometrial cancer. \n\nThe emphasis of this thesis is on the molecular mechanisms of estrogen receptor controlled \nproliferation of the human endometrium and subsequent induction of endometrial cancer. \n\nWe postulated and addressed the following questions in this thesis: \n\n1. What are the molecular mechanisms underlying estrogen-induced growth stimulation and \nprogesterone-induced growth inhibition of endometrial cancer cells? \n2. Does activation of the ER signaling pathway result in activation of IGF and/or EGF \nsignaling, and vice versa, does activation of the IGF and EGF signaling pathways result in \nactivation of ER signaling? \n3. Which genes are regulated by estrogen, tamoxifen, raloxifene and the anti-estrogen \nICI182780 in endometrial cancer cells, and do the four ER-ligands regulate similar genes, \nin the same cellular processes or pathways? \n4. Which genes are regulated in endometrial tissues of tamoxifen-users compared to nonusers, \nand can we, based on the generated gene-expression profiles, elucidate which \npathways are activated by tamoxifen during the early changes which may lead to \nendometrial cancer formation?
Author: Susanne C.J.P. Gielen
Institution: Erasmus University Rotterdam
Language: English
Subfield: Endocrinology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W2167099974
